Burgess, M. A., Bolejack, V., Schuetze, S., Van Tine, B. A., Attia, S., Riedel, R. F., Hu, J. S., Davis, L. E., Okuno, S. H., Priebat, D. A., Movva, S., Reed, D. R., D'Angelo, S. P., Lazar, A. J., Keung, E. Z. Y., Reinke, D. K., Baker, L. H., Maki, R. G., Patel, S., Tawbi, H. A. H. (May 2019) Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts. In: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO).
| Item Type: | Conference or Workshop Item (Poster) |
|---|---|
| Subjects: | diseases & disorders > cancer > drugs and therapies > Immunotherapy diseases & disorders > cancer > cancer types > sarcoma |
| CSHL Authors: | |
| Communities: | CSHL labs > Maki lab |
| Depositing User: | Matthew Dunn |
| Date: | May 2019 |
| Date Deposited: | 18 Oct 2019 18:56 |
| Last Modified: | 18 Oct 2019 19:09 |
| URI: | https://repository.cshl.edu/id/eprint/38616 |
Actions (login required)
 |
Administrator's edit/view item |